Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Development of an electronic health record-based chronic kidney disease registry to promote population health management.

Mendu ML, Ahmed S, Maron JK, Rao SK, Chaguturu SK, May MF, Mutter WP, Burdge KA, Steele DJR, Mount DB, Waikar SS, Weilburg JB, Sequist TD.

BMC Nephrol. 2019 Mar 1;20(1):72. doi: 10.1186/s12882-019-1260-y.

2.

The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.

Idelevich EA, Schaumburg F, Knaack D, Scherzinger AS, Mutter W, Peters G, Peschel A, Becker K.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2551-3. doi: 10.1128/AAC.02859-15. Print 2016 Apr.

3.

Point-of-care photomicroscopy of urine.

Mutter WP, Brown RS.

N Engl J Med. 2011 May 12;364(19):1880-1. doi: 10.1056/NEJMc1013994. No abstract available.

PMID:
21561366
4.

Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.

Khankin EV, Mutter WP, Tamez H, Yuan HT, Karumanchi SA, Thadhani R.

PLoS One. 2010 Feb 16;5(2):e9246. doi: 10.1371/journal.pone.0009246.

5.

Approaching clinical proteomics: current state and future fields of application in cellular proteomics.

Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Müllner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tárnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Wagener C, Wagner O, Schmitz G.

Cytometry A. 2009 Oct;75(10):816-32. doi: 10.1002/cyto.a.20779. Review.

6.

Approaching clinical proteomics: current state and future fields of application in fluid proteomics.

Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Müllner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tarnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Verhuven W, Wagener C, Wagner O, Schmitz G.

Clin Chem Lab Med. 2009;47(6):724-44. doi: 10.1515/CCLM.2009.167. Review.

PMID:
19527139
7.

Thrombotic microangiopathy and renal failure exacerbated by epsilon-aminocaproic acid.

Mutter WP, Stillman IE, Dahl NK.

Am J Kidney Dis. 2009 Feb;53(2):346-50. doi: 10.1053/j.ajkd.2008.07.023. Epub 2008 Sep 21. No abstract available.

PMID:
18805613
8.

Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?

Bdolah Y, Lam C, Rajakumar A, Shivalingappa V, Mutter W, Sachs BP, Lim KH, Bdolah-Abram T, Epstein FH, Karumanchi SA.

Am J Obstet Gynecol. 2008 Apr;198(4):428.e1-6. doi: 10.1016/j.ajog.2007.10.783. Epub 2008 Jan 14.

PMID:
18191808
9.

Molecular mechanisms of preeclampsia.

Mutter WP, Karumanchi SA.

Microvasc Res. 2008 Jan;75(1):1-8. Epub 2007 May 6. Review.

10.

Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.

Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, Karumanchi SA, Russell SJ, Sukhatme VP.

J Natl Cancer Inst. 2006 Jun 7;98(11):756-64.

PMID:
16757700
11.

Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia.

Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, Levine RJ, Karumanchi SA.

Hypertension. 2004 May;43(5):988-92. Epub 2004 Mar 15.

PMID:
15023932
12.

First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.

Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA.

J Clin Endocrinol Metab. 2004 Feb;89(2):770-5.

PMID:
14764795
13.

High-yield, in vitro protein expression using a continuous-exchange, coupled transcription/ translation system.

Martin GA, Kawaguchi R, Lam Y, DeGiovanni A, Fukushima M, Mutter W.

Biotechniques. 2001 Oct;31(4):948-50, 952-3.

14.

Rescue of myeloid lineage-committed preprogenitor cells from cytomegalovirus-infected bone marrow stroma.

Busch FW, Mutter W, Koszinowski UH, Reddehase MJ.

J Virol. 1991 Feb;65(2):981-4.

15.

Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes.

Jonjić S, Mutter W, Weiland F, Reddehase MJ, Koszinowski UH.

J Exp Med. 1989 Apr 1;169(4):1199-212.

16.

Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host.

Mutter W, Reddehase MJ, Busch FW, Bühring HJ, Koszinowski UH.

J Exp Med. 1988 May 1;167(5):1645-58.

18.

Molecular analysis of herpesviral gene products recognized by protective cytolytic T lymphocytes.

Koszinowski UH, Reddehase MJ, Keil GM, Volkmer H, Jonjic S, Messerle M, del Val M, Mutter W, Münch K, Bühler B.

Immunol Lett. 1987 Dec;16(3-4):185-92. Review.

PMID:
2832318
19.

CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity.

Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH.

J Virol. 1987 Oct;61(10):3102-8.

20.

Stable expression of clonal specificity in murine cytomegalovirus-specific large granular lymphoblast lines propagated long-term in recombinant interleukin 2.

Reddehase MJ, Zawatzky R, Weiland F, Bühring HJ, Mutter W, Koszinowski UH.

Immunobiology. 1987 Aug;174(4-5):420-31.

PMID:
2824342
21.
22.

The role of Cu(I)-thiolate clusters during the proteolysis of Cu-thionein.

Weser U, Mutter W, Hartmann HJ.

FEBS Lett. 1986 Mar 3;197(1-2):258-62.

23.

The kinetics of the thermal decomposition of gaseous methyl ethyl ketone.

WARING CE, MUTTER WE.

J Am Chem Soc. 1948 Dec;70(12):4073-81. No abstract available.

PMID:
18105941

Supplemental Content

Loading ...
Support Center